Back
Vivos Therapeutics Quote, Financials, Valuation and Earnings
Multimillionaire Trader Reveals His #1 Gold Pick
Click here to learn more about this game-changing opportunity.
Sell
40
VVOS
Vivos Therapeutics
Last Price:
2.43
Seasonality Move:
35.01%
7 Day Trial
ALL ACCESS PASS
$
7
Don't put a penny in AI stocks until you read this
Discover this under-the-radar AI stock now, ahead of the crowd.Vivos Therapeutics Price Quote
$2.43
-0.10 (-3.95%)
(Updated: October 17, 2024 at 6:55 PM ET)
Vivos Therapeutics Key Stats
Sell
40
Vivos Therapeutics (VVOS)
is a Sell
Day range:
$2.42 - $2.55
52-week range:
$1.91 - $48.79
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.35
P/B ratio:
1.3%
Volume:
75.2K
Avg. volume:
2.8M
1-year change:
-68.33%
Market cap:
$8.3M
Revenue:
$13.8M
EPS:
$-7.03
How Much Does Vivos Therapeutics Make?
-
How Much Are Vivos Therapeutics's Sales Annually?
VVOS Revenues are $13.8M -
How Much Profit Does Vivos Therapeutics's Make A Year?
VVOS net income is -$13.6M
Is Vivos Therapeutics Growing As A Company?
-
What Is Vivos Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.19% -
What Is Vivos Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Vivos Therapeutics Stock Price Performance
-
Did Vivos Therapeutics Stock Go Up Last Month?
Vivos Therapeutics share price went down by -14.24% last month -
Did VVOS's Share Price Rise Over The Last Year?
VVOS share price fell by -68.33% over the past 1 year
What Is Vivos Therapeutics 52-Week High & Low?
-
What Is Vivos Therapeutics’s 52-Week High Share Price?
Vivos Therapeutics has traded as high as $48.79 over the past 52 weeks -
What Is Vivos Therapeutics’s 52-Week Low Share Price?
Vivos Therapeutics has traded as low as $1.91 over the past 52 weeks
Vivos Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Vivos Therapeutics?
-
How Much Debt Does Vivos Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Vivos Therapeutics Have?
Cash and short term investments quarterly total is $6.9M -
What Is Vivos Therapeutics’s Book Value Per Share?
Book value per share is 1.87
Is Vivos Therapeutics Cash Flow Positive?
-
What Is VVOS Cash Flow From Operations?
Cash flow from operations (TTM) is -$11.1M -
What Is Vivos Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $14.6M -
What Is Vivos Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$530K
Vivos Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
VVOS return on invested capital is -634.48% -
What Is Vivos Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -96.45% -
What Is VVOS Return On Equity?
ROE is a measure of profitability and is -634.48%
Vivos Therapeutics Earnings Date & Stock Price
-
What Is Vivos Therapeutics's Stock Price Today?
A single share of VVOS can be purchased today for 2.53 -
What Is Vivos Therapeutics’s Stock Symbol?
Vivos Therapeutics trades on the nasdaq under the ticker symbol: VVOS -
When Is Vivos Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Vivos Therapeutics is scheduled on November 14, 2024 -
When Is VVOS's next ex-dividend date?
Vivos Therapeutics's next ex-dividend date is October 18, 2024 -
How To Buy Vivos Therapeutics Stock?
You can buy Vivos Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Vivos Therapeutics Competitors
-
Who Are Vivos Therapeutics's Competitors?
Below is a list of companies who compete with Vivos Therapeutics or are related in some way:
Vivos Therapeutics Dividend Yield
-
What Is VVOS Dividend Yield?
Vivos Therapeutics’s dividend yield currently is 0% -
What Is Vivos Therapeutics’s Payout Ratio?
Vivos Therapeutics’s payout ratio is 0% -
When Did Vivos Therapeutics Last Pay A Dividend?
The latest dividend pay date is October 18, 2024 -
What Is Vivos Therapeutics’s Dividend Per Share?
Vivos Therapeutics pays a dividend of $0.00 per share
Vivos Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 42.86% |
| Revenue: | 19.41% | 12.61% |
Analyst Recommendations
| Buy Recommendations: | 2 |
|---|---|
| Hold Recommendations: | 0 |
| Sell Recommendations: | 0 |
| Price Target: | 7.43 |
| Upside from Last Price: | 193.48% |